COVID-19 medicine share in pharma revenue in Russia 2021, by company

Published by Statista Research Department, May 4, 2023
Over 91 percent of the total revenue of the Russian pharmaceutical company R-Pharm came from sales of medicines for treatment of the coronavirus (COVID-19) in 2021. Furthermore, COVID-19 drug sales accounted for almost 46 percent of the revenue of Pfizer in Russia.

Share of medicines for COVID-19 treatment in the total revenue in Russia in 2021, by pharmaceutical company

© Statista 2025
Download
Show detailed source information?
Register for free
Already a member?
Log in
Source

Use Ask Statista Research Service

Release date

February 2022

Region

Russia

Survey time period

2021

Supplementary notes

Companies with the largest share of COVID-19 medicines in their revenue are presented.

Citation formats
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts

Statistics on " Pharmaceutical industry in Russia "

The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics
The most important statistics

Other statistics that may interest you Pharmaceutical industry in Russia

Overview

8

Segments

8

Companies and brands

8

Pharmacies

4

Online retail

6

Trade

4

Further Content: You might find this interesting as well

Topics

Coronavirus (COVID-19) in RussiaCOVID-19 impact on the gaming industry worldwidePfizerBioNTechCoronavirus disease (COVID-19) pandemic
Access all statistics starting from $2,388 USD yearly *

* For commercial use only

Basic Account

For single users
$0 USD
Always free
Access limited to Free Statistics. Premium Statistics are not included.
  • Free Statistics
Based on your interests

Starter Account

For single users
$199 USD
per month, billed annually 1
Buy now
  • Free Statistics
  • Premium Statistics

    • The statistic on this page is a Premium Statistic and is included in this account.

Professional Account

For teams of up to 5 people
$1,299 USD
per month, billed annually 1
Buy now
  • Free + Premium Statistics
  • Reports
  • Market Insights

1 All prices do not include sales tax. The account requires an annual contract and will renew after one year to the regular list price.

Compare accounts
Learn more about how Statista can support your business.